沃华医药(002107) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥181,524,998.96, a decrease of 18.99% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was ¥11,828,133.46, down 41.44% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,455,276.64, a decline of 41.26% compared to the previous year[3]. - The basic earnings per share for Q3 2024 were ¥0.02, a decrease of 33.33% compared to the same period last year[3]. - The net profit for Q3 2024 was CNY 20,139,194.30, a decrease of 56.6% compared to CNY 46,438,288.71 in Q3 2023[15]. - Operating profit for Q3 2024 was CNY 26,435,003.77, down 44.5% from CNY 47,714,006.59 in the same period last year[15]. - Total revenue from operating activities was CNY 655,440,762.39, a decline of 20.6% compared to CNY 826,064,891.56 in Q3 2023[18]. - The total profit for Q3 2024 was CNY 25,171,154.91, a decrease of 47.8% from CNY 48,211,892.47 in Q3 2023[15]. Assets and Liabilities - The total assets at the end of Q3 2024 were ¥984,788,339.45, representing a decrease of 13.97% from the end of the previous year[3]. - The equity attributable to shareholders at the end of Q3 2024 was ¥683,874,554.35, down 15.07% from the end of the previous year[3]. - The total assets at the end of the period are ¥984,788,339.45, down from ¥1,144,706,388.58 at the beginning of the period, a decrease of 13.9%[12]. - The total liabilities amount to ¥275,473,511.60, down from ¥311,228,355.03, indicating a reduction of 11.5%[13]. Cash Flow and Expenses - The net cash flow from operating activities for the year-to-date was ¥66,637,544.70, a decrease of 27.47% compared to the same period last year[3]. - The company reported a net cash flow from operating activities of CNY 66,637,544.70, a decrease of 27.4% from CNY 91,875,569.97 in Q3 2023[18]. - Research and development expenses decreased to CNY 29,383,363.35, down 19.5% from CNY 36,523,429.87 in the previous year[15]. - Total sales expenses for Q3 2024 were CNY 302,748,648.37, a reduction of 23.5% compared to CNY 396,000,546.49 in Q3 2023[15]. Inventory and Receivables - Cash and cash equivalents at the end of the period are ¥327,460,207.48, down from ¥401,100,106.17 at the beginning of the period, indicating a decrease of 18.3%[11]. - Accounts receivable decreased to ¥64,229,988.83 from ¥79,482,613.10, a reduction of 19.2%[11]. - Inventory has decreased to ¥115,227,500.42 from ¥149,086,389.06, representing a decline of 22.7%[11]. - The cash and cash equivalents at the end of Q3 2024 were CNY 318,797,669.66, down from CNY 362,901,383.52 at the end of Q3 2023[19]. Government Support and Market Activity - The company received government subsidies amounting to ¥1,234,235.36 during the reporting period, contributing to its financial performance[4]. - The company has not reported any new product developments or market expansion strategies during this period[12]. Profitability Metrics - The weighted average return on net assets was 1.74%, down 0.80% year-on-year[3]. - The company incurred financial expenses of CNY -3,870,821.15, slightly higher than CNY -3,749,505.41 in the previous year[15].